---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053978"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:31:17.252997+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corbus Q1 net loss narrows to $6.9M; raised $116M, cash runway through Q1 2027

## Summary
- Net loss of $6.9M ($0.83/diluted share) vs $17.7M ($4.24) in Q1 2023, driven by lower operating expenses.
- Raised $116M in Q1 via public offering ($94.5M) and ATM ($21.1M); cash, equivalents & investments $120.1M.
- Phase 1 data for CRB-701 (next-gen Nectin-4 ADC) to be presented at ASCO 2024 on June 1, 2024.
- Appointed Dr. Dominic Smethurst as Chief Medical Officer; expects first CRB-913 patient dosed in Q1 2025.
- IND cleared for CRB-601 (anti-αvβ8 mAb); Phase 1 initiation expected summer 2024.

## SEC filing metadata
- accession: 0000950170-24-053978
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024053978/0000950170-24-053978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024053978/crbp-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053978
- JSON: https://secwatch.observer/filing/0000950170-24-053978.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053978.txt

## Key facts
- Earnings Releases
  Corbus Pharmaceuticals Holdings, Inc. reported the three months ended March 31, 2024 results: net income approximately $6.9 million, EPS a net loss per diluted share of $0.83.
  - Period: the three months ended March 31, 2024
  - Net income: approximately $6.9 million
  - EPS: a net loss per diluted share of $0.83
  - Result: reported results
  source text: The Company reported a net loss of approximately $6.9 million, or a net loss per diluted share of $0.83, for the three months ended March 31, 2024, compared to a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017024053978/0000950170-24-053978-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.